ArticleCancers2023

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.

Martin Salzmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.